8-K: DocGo Refinances Debt, Issues Warrants Amid Acquisition

DocGo Inc. has amended and restated its credit agreement, securing new and existing term loans totaling $102 million, and issued a warrant for 4 million shares as part of the transaction.

Summary

• DocGo Inc. has entered into an Amended and Restated Credit Agreement and Guaranty, consolidating and expanding its credit facilities.
• The new agreement includes existing term loans of $52 million, a new $12.5 million term loan, another $12.5 million term loan to be funded upon merger completion, and a $25 million delayed draw term loan facility.
• The total principal amount available under the new credit facilities is $102 million.
• Interest on the term loans is set at Term SOFR plus a 7.50% margin, with a 3.50% floor.
• The maturity date for these loans is December 6, 2029.
• As part of the credit agreement, DocGo issued a warrant to the administrative agent to purchase up to 4,000,000 shares of its common stock at an exercise price of $0.5039 per share.
• The company also terminated its existing revolving credit facility with Citibank, N.A.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the refinancing of debt and the strategic acquisition, though the issuance of warrants introduces potential dilution.

Positives

• Secured a significant credit facility totaling $102 million, providing substantial financial flexibility.
• The new credit agreement consolidates existing debt and introduces new funding tranches, including a delayed draw facility for future needs.
• The merger with Hicuity Health, Inc. is progressing, with a related term loan to be funded upon closing.
• The company terminated its previous revolving credit facility, simplifying its debt structure.

Negatives

• Issuance of a warrant to purchase 4,000,000 shares of common stock at $0.5039 per share introduces potential future dilution for existing shareholders.
• The credit agreement contains restrictive covenants, including limitations on additional indebtedness, mergers, acquisitions, and asset disposals.
• Stock repurchases are generally prohibited, with an exception for up to $40 million under the existing program, subject to strict conditions and agent consent.

Risks

• The credit agreement includes mandatory prepayment provisions triggered by casualty events, incurrence of impermissible indebtedness, and certain asset sales.
• Breach of covenants or events of default could lead to the termination of commitments and acceleration of all outstanding loans.
• The warrant's automatic exercise upon a Liquidity Event or Acquisition could lead to significant dilution at a critical juncture for the company.

Future Outlook

The delayed draw term loan facility of $25,000,000 is available until December 31, 2027, subject to certain conditions, indicating potential future funding needs or strategic opportunities. The warrant is exercisable for ten years and may automatically exercise under specific conditions like a Liquidity Event or Acquisition.

Industry Context

StockSavvy.ai notes that DocGo's strategic move to refinance its debt and secure new credit facilities, alongside the pending acquisition of Hicuity Health, aligns with industry trends of consolidation and the need for robust financing to support growth and operational integration in the healthcare services sector.

Stakeholder Impact

• Shareholders: Potential dilution from the exercise of 4,000,000 warrants.
• Creditors: The new credit agreement restructures and potentially increases the company's debt obligations.
• Lenders: Perceptive Credit Holdings IV, LP is the administrative agent for the new credit facility and the recipient of the warrant.

Next Steps

• Funding of Term Loan C upon the consummation of the Merger.
• Availability of the delayed draw term loan facility (Term Loan D) until December 31, 2027.
• Potential exercise of the issued warrant by the administrative agent within the ten-year Exercise Period.

Key Dates

Recommendation

The refinancing of debt and progress on the Hicuity Health acquisition are positive, but the issuance of a significant warrant introduces dilution risk. The overall impact on the stock price is likely to be mixed, warranting a hold recommendation until the benefits of the acquisition and the impact of potential dilution become clearer.

Keywords

Credit Agreement, Term Loan, Warrant, Merger, Debt Refinancing, Hicuity Health, Ambulnz, Security Agreement